Halozyme Therapeutics (HALO) Falls Short of Q4 Views
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
EPS Growth %: +30.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +30.8%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme prices $1.3B convertible notes offering due 2033
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Radiant Logistics (RLGT) Tops Q4 EPS by 9c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
